Incyte Corporation (INCY) News Headlines

▮ More

Date

Headline

5/20/2022 8:29:07 AM Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment

5/20/2022 8:19:00 AM Lilly : CHMP Issues Positive Opinion For OLUMIANT For Treatment Of Adults With Severe Alopecia Areata

5/11/2022 7:04:22 AM Eli Lilly, Incyte Announce FDA Approval Of OLUMIANT For Hospitalized Patients With COVID-19

5/11/2022 6:51:49 AM Lilly And Incyte: FDA Approves OLUMIANT For Certain Hospitalized Patients With COVID-19

5/3/2022 8:12:32 AM Incyte Q1 Results Miss Estimates

5/3/2022 7:10:46 AM Incyte Q1 GAAP EPS $0.17; Non-GAAP EPS $0.55

5/3/2022 7:00:33 AM Incyte Q1 22 Earnings Conference Call At 8:00 AM ET

4/13/2022 8:41:56 AM Why BriaCell Therapeutics Is Rising In Pre-market?

3/22/2022 10:23:01 PM MorphoSys : Swissmedic Temporarily Approves Minjuvi - Lenalidomid Combination For DLBCL Treatment

3/7/2022 8:50:11 AM Incyte To Present At Cowen Health Care Conference; Webcast At 9:50 AM ET

2/8/2022 7:10:57 AM Incyte Corporation Q4 Profit Increases, but misses estimates

2/8/2022 7:08:02 AM Incyte Q4 GAAP EPS $2.54; Non-GAAP EPS $0.10

2/8/2022 7:00:30 AM Incyte Q4 21 Earnings Conference Call At 8:00 AM ET

1/28/2022 8:16:35 AM Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts

1/24/2022 2:41:25 AM Innovent : Pemazyre Approved In Hong Kong For Treatment Of Adults With Metastatic Cholangiocarcinoma

1/10/2022 7:00:10 AM Incyte To Present At J. P. Morgan Healthcare Conference; Webcast At 7:30 AM ET

1/6/2022 2:00:09 PM Incyte To Present At Goldman Sachs Healthcare CEOs Unscripted Conference; Webcast At 3:00 PM ET

12/11/2021 1:21:54 PM Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

12/11/2021 12:06:52 PM MorphoSys Announces Additional Results From RE-MIND2 Study Of Tafasitamab - Lenalidomide For DLBCL

11/9/2021 8:32:46 AM Lilly : OLUMIANT Long-Term Safety Profile Established Up To 9.3 Years In Analysis On Rheumatoid Arthritis